Dermata Therapeutics Inc Net Assets
Dermata Therapeutics Inc net assets. Based on the latest financial reports, Dermata Therapeutics Inc (DRMA) has net assets worth $3.49 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.32 Million) and total liabilities ($1.83 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore DRMA shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.49 Million |
| % of Total Assets | 65.55% |
| Annual Growth Rate | N/A |
| 5-Year Change | -38.43% |
| 10-Year Change | N/A |
| Growth Volatility | 148.06 |
Net Assets of Dermata Therapeutics Inc (2019–2025)
Net assets of Dermata Therapeutics Inc from 2019 to 2025. This chart illustrates how Dermata Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See Dermata Therapeutics Inc balance sheet independence to measure how much of total assets are equity-financed.
Annual Net Assets for Dermata Therapeutics Inc (2019–2025)
The table below shows the annual net assets of Dermata Therapeutics Inc from 2019 to 2025. For live market cap and overall valuation, see Dermata Therapeutics Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $6.22 Million | +298.66% |
| 2024-12-31 | $1.56 Million | -75.44% |
| 2023-12-31 | $6.36 Million | +5.53% |
| 2022-12-31 | $6.02 Million | -40.42% |
| 2021-12-31 | $10.11 Million | +418.04% |
| 2020-12-31 | $-3.18 Million | -1412.16% |
| 2019-12-31 | $-210.16K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Dermata Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4839062800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Dermata Therapeutics Inc Net Assets Breakdown (December 2025)
Dermata Therapeutics Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $266.00 | 0.00% |
| Other Components | $79.46 Million | 1276.75% |
| Total Equity | $6.22 Million | 100.00% |
Dermata Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Dermata Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Maple Peak Investments Inc
V:MAP
|
$3.41 Million |
|
Pinnacle Minerals Ltd
AU:PIM
|
$3.43 Million |
|
J-Star Holding Co., Ltd. Ordinary Shares
NASDAQ:YMAT
|
$3.43 Million |
|
Autozi Internet Technology (Global) Ltd. Class A Ordinary Shares
NASDAQ:AZI
|
$3.43 Million |
|
Hochdorf Holding AG
SW:HOCN
|
$3.41 Million |
|
Focus Universal Inc
NASDAQ:FCUV
|
$3.41 Million |
|
MGO Global Inc. Common Stock
NASDAQ:MGOL
|
$3.41 Million |
|
Poddar Housing and Development Limited
NSE:PODDARHOUS
|
$3.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dermata Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,561,094 to 6,223,380, a change of 4,662,286 (298.7%).
- Net loss of 7,558,557 reduced equity.
- Share repurchases of 367 reduced equity.
- New share issuances of 12,167,852 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.56 Million | -121.45% |
| Share Repurchases | $367.00 | -0.01% |
| Share Issuances | $12.17 Million | +195.52% |
| Other Changes | $53.36K | +0.86% |
| Total Change | $- | 298.66% |
Book Value vs Market Value Analysis
This analysis compares Dermata Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.13x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-60.56 | $0.85 | x |
| 2020-12-31 | $-915.83 | $0.85 | x |
| 2021-12-31 | $194.17 | $0.85 | x |
| 2022-12-31 | $87.19 | $0.85 | x |
| 2023-12-31 | $325.97 | $0.85 | x |
| 2024-12-31 | $10.20 | $0.85 | x |
| 2025-12-31 | $6.72 | $0.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dermata Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -121.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.26x
- Recent ROE (-121.45%) is above the historical average (-181.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.70 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.92 Million |
| 2021 | -78.64% | 0.00% | 0.00x | 1.15x | $-8.96 Million |
| 2022 | -159.60% | 0.00% | 0.00x | 1.15x | $-10.21 Million |
| 2023 | -122.66% | 0.00% | 0.00x | 1.26x | $-8.43 Million |
| 2024 | -787.11% | 0.00% | 0.00x | 2.26x | $-12.44 Million |
| 2025 | -121.45% | 0.00% | 0.00x | 1.26x | $-8.18 Million |
Industry Comparison
This section compares Dermata Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dermata Therapeutics Inc (DRMA) | $3.49 Million | 0.00% | 0.53x | $3.41 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Dermata Therapeutics Inc
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in… Read more